Core Viewpoint - Iradimed Corporation will release its 2025 fourth quarter and full year financial results on February 10, 2026, followed by a conference call to discuss the results and answer questions [1]. Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company was the first to create an infusion delivery system that mitigates dangers associated with standard infusion pumps during MRI, which can cause radio frequency interference [3]. - The patented MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, ensuring safe and reliable delivery of anesthesia and IV fluids during MRI scans [3]. Product Details - The 3880 MRI-compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and blood pressure monitoring, facilitating uninterrupted vital signs monitoring for critically ill patients [4]. - The compact design of the Iradimed 3880 allows for easy transport with patients, enhancing safety and reducing time away from critical care units [4].

Core Points - Iradimed Corporation will release its 2025 third quarter financial results on November 3, 2025, before market opening [1] - A conference call will be held on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions [1][2] Company Overview - Iradimed Corporation specializes in developing MRI-compatible medical devices, notably a non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3] - The patented MRidium® MRI compatible IV infusion pump system utilizes a non-magnetic ultrasonic motor and non-ferrous parts to deliver anesthesia and IV fluids safely during MRI scans [3] - The 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, operating in magnetic fields up to 30,000 gauss, ensuring patient safety and uninterrupted monitoring during MRI procedures [4] - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2, and advanced multi-gas anesthetic agent measurements, facilitating effective communication of vital signs to clinicians [4]

Core Viewpoint - Iradimed Corporation will release its 2025 second quarter financial results on August 1, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company has developed the patented MRidium® MRI compatible IV infusion pump system, which eliminates dangers associated with standard infusion pumps that contain magnetic components [3]. - The Iradimed 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. Product Features - The MRidium® system provides accurate and safe delivery of anesthesia and IV fluids during MRI scans, crucial for critically ill patients and children who require sedation [3]. - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit capabilities [4].

Company Overview - IRADIMED CORPORATION is a leader in developing innovative MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company has developed the MRidium® MRI compatible IV infusion pump system, which features a non-magnetic ultrasonic motor and non-ferrous parts to ensure safe and predictable delivery of anesthesia and IV fluids during MRI scans [3]. Product Offerings - The 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - The Iradimed 3880 system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit, facilitating effective communication of vital signs to clinicians [4]. Upcoming Events - The company will release its 2025 first quarter financial results before the market opens on May 5, 2025, followed by a conference call at 9:00 a.m. Eastern Time to discuss the results [1]. - Interested participants can register for the conference call through a provided link, and a recording will be available on the company's website after the call [2].

Core Viewpoint - Iradimed Corporation will release its 2025 first quarter financial results on May 5, 2025, and will host a conference call to discuss these results [1] Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3] - The company has developed the MRidium® MRI compatible IV infusion pump system, which eliminates dangers associated with standard infusion pumps that contain magnetic components [3] - The Iradimed 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4] Product Features - The MRidium® system provides accurate and safe delivery of anesthesia and IV fluids during MRI scans, crucial for critically ill patients and children who require sedation [3] - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit capabilities [4]